Latest Ratios: P/E Ratio -826.4x · EV/EBITDA N/A · ROE -54.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.9B | $8.4B | $44M | $300M | $450M | — | — | — |
| Enterprise Value | $2.9B | $8.4B | $41M | $299M | $445M | — | — | — |
| P/E Ratio → | -826.39 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 605.35 | 1733.65 | 5.32 | 25.01 | 26.36 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -54.8% | -54.8% | -42.6% | -40.4% | -113.5% | — | — | — |
| ROA | -50.5% | -50.5% | -40.9% | -38.3% | -80.9% | -315.3% | -214.5% | -160.7% |
| ROIC | -67.9% | -67.9% | -43.8% | -42.2% | -103.3% | — | -3803.4% | — |
| ROCE | -56.5% | -56.5% | -46.8% | -42.6% | -113.3% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.01 | 0.04 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.39 | -0.35 | -0.09 | -0.33 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($544415)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.39 | 7.39 | 41.92 | 19.15 | 28.46 | 0.02 | 0.12 | 0.12 |
| Quick Ratio | 7.39 | 7.39 | 41.92 | 19.24 | 28.51 | 0.02 | 0.12 | 0.12 |
| Cash Ratio | 7.38 | 7.38 | 41.13 | 19.06 | 28.41 | 0.01 | 0.12 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $494M | $494M | $494M | $494M | $480M | $480M | $480M |
Clinical Trial Funding Exhaustion
According to recent SEC filings, RGC's P/B ratio of 659.27 reflects a market valuation detached from tangible book value, suggesting that investors are pricing the company based on speculative clinical potential rather than any established earnings multiple or historical asset-based valuation metrics common in the broader healthcare sector.
The extreme P/B multiple indicates that the market is assigning significant value to intangible intellectual property, yet the lack of revenue makes traditional P/E or EV/EBITDA analysis impossible. Investors should monitor whether this premium can be sustained as the cash runway shortens and the probability of successful commercialization remains unproven.
Based on reported figures, the company's ROIC has trended into negative territory, reaching -27.7% in 2025Q4, which highlights a consistent decay in the firm's ability to generate returns on invested capital as research expenditures continue to outpace any potential for near-term commercial value creation or operational efficiency.
The persistent negative ROIC suggests that every dollar of capital deployed is currently destroying shareholder value rather than compounding it. This trend warrants further investigation into whether the current R&D spend is effectively moving the company toward a commercial inflection point or simply funding ongoing operational deficits.
As reported in financial statements, the company's current ratio has fluctuated significantly, settling at 7.39 in 2025Q4, which, while appearing high, masks the reality that the firm's liquidity is rapidly depleting due to the absence of revenue and the ongoing cash burn required to sustain clinical operations.
While the current ratio suggests a short-term ability to cover liabilities, the absolute cash balance of $2.4 million is insufficient to support long-term clinical trials. Investors should be wary of the company's reliance on external financing, as the current liquidity position provides a very narrow margin for error.
The most commonly misapplied metric for RGC is the current ratio, which, as indicated by historical data, provides a false sense of security by ignoring the company's lack of recurring revenue and the high probability of future dilutive equity raises to fund ongoing research and development activities.
Analysts should instead focus on the 'cash burn rate' and 'runway in months' rather than traditional liquidity ratios. Relying on standard balance sheet ratios obscures the fundamental risk that the company's survival is entirely contingent on external capital markets rather than internal operational cash generation.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RGC stock.
Regencell Bioscience Holdings Limited's current P/E ratio is -826.4x. This places it at the 50th percentile of its historical range.
Regencell Bioscience Holdings Limited's return on equity (ROE) is -54.8%. The historical average is -62.8%.
Based on historical data, Regencell Bioscience Holdings Limited is trading at a P/E of -826.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.